|
| Monday, October 16, 2023 |
|
|
Eisai to Present New Data from LEQEMBI (Lecanemab-Irmb) Phase 3 Clarity Ad Study and Other Alzheimer's Disease Pipeline Research at The Clinical Trials on Alzheimer's Disease (CTAD) Conference |
| Eisai Co. Ltd announced today that the company will present new data from the phase 3 Clarity AD study for its Alzheimer's disease (AD) treatment LEQEMBI (lecanemab-irmb) 100 mg/mL injection for intravenous use and new data on the subcutaneous formulation in development at the 16th annual Clinical Trials on Alzheimer's Disease (CTAD) conference. more info >> |
|
|
エーザイ、第16回アルツハイマー病臨床試験会議（CTAD）において「レケンビ」の臨床第III相Clarity AD試験の新規データを含むアルツハイマー病領域の最新データを発表 |
| more info >> |
|
| Wednesday, October 11, 2023 |
|
|
Eisai to Present Research from Oncology Portfolio and Pipeline at ESMO Congress 2023 |
| Eisai Co., Ltd. announced today the presentation of research across various types of cancer from its oncology portfolio and pipeline during the European Society for Medical Oncology (ESMO) Congress 2023, which is taking place virtually and in-person in Madrid, Spain from October 20 to 24. more info >> |
|
| Wednesday, October 4, 2023 |
|
|
Eisai: Notice of Absorption-Type Merger (Simplified Merger/Short-Form Merger) of KAN Research Institute, Inc. |
| Eisai Co., Ltd. hereby announcesthat the Company has today decided to absorb and merge with KAN Research Institute, Inc., the Company's wholly owned subsidiary on April 1, 2024. more info >> |
|
| Thursday, September 28, 2023 |
|
|
Eisai Launches New "Innovation" Page on Corporate Website |
| Eisai Co., Ltd. announced today that it has launched a new "Innovation" page on its corporate website. more info >> |
|
| Monday, December 18, 2017 |
|
|
エーザイ、小中高校生を対象とした、認知症を知り自分にできることを考えるための教材を販売開始 |
| エーザイ株式会社（本社：東京都、代表執行役 CEO：内藤晴夫、以下 エーザイ）は、日本において、小学生および中高生を対象とした、認知症を知り自分にできることを考えるための教材を作成し、本日より自治体や教育機関、医療・介護関係者などに向けた販売を開始することをお知らせします。 more info >> |
|
| Thursday, September 28, 2023 |
|
|
Tokio Marine Nichido and Eisai Co-Develop Industry's First "Dementia Care Support Insurance" |
| Tokio Marine & Nichido Fire Insurance Co., Ltd. and Eisai Co., Ltd. announced that they have co-developed "Dementia Care Support Insurance" to financially support early detection and early treatment for dementia as a part of their business alliance for the realization of a Dementia Inclusive Society. more info >> |
|
| Monday, September 25, 2023 |
|
|
"LEQEMBI Intravenous Infusion" (Lecanemab) Approved for the Treatment of Alzheimer's Disease in Japan |
| Eisai Co., Ltd. and Biogen Inc. announced today that humanized anti- soluble aggregated amyloid-beta (Abeta) monoclonal antibody "LEQEMBI" Intravenous Infusion (200 mg, 500mg, lecanemab) has been approved in Japan as a treatment for slowing progression of mild cognitive impairment (MCI) and mild dementia due to Alzheimer's disease (AD). more info >> |
|
| Thursday, September 21, 2023 |
|
|
Eisai: Release of Dementia Disease Awareness Videos for World Alzheimer's Day, September 21 |
| Eisai Co., Ltd. announced today on World Alzheimer's Day, that it has released a dementia awareness video, "Life Goes On 2023: Two Memories, One Story", on its dementia information website "Sodan.e-65" and YouTube, which are intended to deepen the understanding of dementia. more info >> |
|
| Tuesday, September 12, 2023 |
|
|
Eisai Establishes Theoria Technologies Co., Ltd., A New Digital Business Company To Build A Dementia Ecosystem |
| Eisai Co., Ltd. announced today that it has established a digital business company Theoria technologies Co., Ltd. ("Theoria technologies") which will accelerate the development of a dementia ecosystem. Theoria technologies is a wholly owned subsidiary of Eisai. more info >> |
|
|
|
|
